EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 11800 participants.
Also called NCT07064473
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 11,800 participants
- Sponsor
- Registry
-
NCT07064473 -
U1111-1319-9064 -
2025-521188-11-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Hong Kong SAR China, Hungary, India, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Philippines, Poland, Portugal, Puerto Rico, Romania, Saudi Arabia, Serbia, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Türkiye, United Kingdom, Vietnam
- Registry status
- Recruiting
Technical summary
Registry record NCT07064473. Randomized; quadruple masking; primary purpose treatment. Start 2025-07-22 (actual); primary completion 2029-12-14 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Hypertension
- Condition
- Cardiovascular Diseases
- Intervention (Drug)
- Vicadrostat
- Intervention (Drug)
- Empagliflozin
- Intervention (Drug)
- Placebo matching Vicadrostat
- Lead sponsor
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct07064473- Content hash
e6512b246efe37a59d8d22c46706b760d7b108c320caff2957d84c5555040912